Structure via PubChem · Public domain (PubChem)
abexinostat
Sign in to saveAlso known as CRA-024781, PCI-24781
Abexinostat (INN, formerly PCI-24781) is an experimental drug candidate for cancer treatment. It was developed by Pharmacyclics and licensed to Xynomic. , it was in Phase II clinical trials for B-cell lymphoma. Pre-clinical study suggests the potential for treatment of different types of cancer as well.
Chemical data
- Formula
- C21H23N3O5
- Molecular weight
- 397.4 g/mol
- IUPAC name
- 3-[(dimethylamino)methyl]-N-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]-1-benzofuran-2-carboxamide
- SMILES
- CN(C)CC1=C(OC2=CC=CC=C21)C(=O)NCCOC3=CC=C(C=C3)C(=O)NO
- InChIKey
- MAUCONCHVWBMHK-UHFFFAOYSA-N
- XLogP
- 2.2
- Polar surface area
- 104 Ų
- H-bond donors
- 3
- H-bond acceptors
- 6
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Phase 3
- Molecule type
- Small molecule
- Indications
- Hodgkins lymphoma, neoplasm, sarcoma, non-Hodgkins lymphoma
via ChEMBL · EBI
Research
57 papers- Safety, pharmacokinetics, and efficacy of abexinostat, an novel histone deacetylase inhibitor, in Chinese patients with relapsed/refractory B cell non-Hodgkin lymphoma: a Phase 1 study.BMC cancer · 2025
- The Bioequivalence of Abexinostat (CRA-024781) Tosylate Tablets (20 mg) in Chinese Healthy Subjects Under Fasting Conditions.Clinical pharmacology in drug development · 2024
- Development of an UPLC-MS/MS method for quantitative analysis of abexinostat levels in rat plasma and application of pharmacokinetics.BMC chemistry · 2024
- A phase 1 trial of abexinostat with ibrutinib in relapsed/refractory mantle cell lymphoma and non-germinal center diffuse large B cell lymphoma.Leukemia & lymphoma · 2024
- Time dependent modulation of tumor radiosensitivity by a pan HDAC inhibitor: abexinostat.Oncotarget · 2017
via PubMed
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 397.163771
- Has use
- medication
Show 3 more facts
- chemical formula
- C₂₁H₂₃N₃O₅
- canonical SMILES
- CN(C)CC1=C(OC2=CC=CC=C21)C(=O)NCCOC3=CC=C(C=C3)C(=O)NO
- subject has role
- histone deacetylase inhibitors
Sources (2)
via Wikidata · CC0
~2 min read
Encyclopedic overview
4 sectionsContents
- Progress
- Research
- Safety and efficacy
- References
{{Chembox | Verifiedfields = changed | verifiedrevid = 486401721 | ImageFile = Abexinostat.svg | ImageClass = skin-invert-image | ImageSize = | IUPACName = 3-[(Dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide | OtherNames = PCI-24781; CRA-024781 | Section1 = | Section2 = | Section3 = | Section5 = }}
Abexinostat (INN, formerly PCI-24781) is an experimental drug candidate for cancer treatment. It was developed by Pharmacyclics and licensed to Xynomic. , it was in Phase II clinical trials for B-cell lymphoma. Pre-clinical study suggests the potential for treatment of different types of cancer as well.
Excerpted from Wikipedia’s “abexinostat” article, available under the CC BY-SA 4.0 licence.